Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant.
The effect of replacing a standard citrate anticoagulant with one containing half the amount of citrate on the in vitro properties of components prepared from blood donations was investigated. This resulted in a significant improvement in factor VIII stability such that there was little loss during overnight storage, and this was reflected in the factor VIII yield in cryoprecipitate. The quality of cellular components in red cell units stored up to 35 days or platelet concentrates stored up to 7 days was not adversely affected. Although initial levels were similar to those in standard anticoagulant, the extent of fibrinopeptide A generation and complement C3 breakdown in red cell units stored for 35 days in half-strength citrate was somewhat increased.
D000925:Anticoagulants / Q000494:pharmacology*; D001773:Blood Cells / Q000502:physiology*; D001792:Blood Platelets / Q000166:cytology / Q000648:ultrastructure; D001793:Blood Preservation / Q000379:methods*; D001798:Blood Proteins / Q000378:metabolism; D002951:Citrates / Q000494:pharmacology*; D019343:Citric Acid; D003176:Complement C3 / Q000378:metabolism; D015926:Complement C3a; D004912:Erythrocytes / Q000166:cytology; D005169:Factor VIII / Q000032:analysis / Q000378:metabolism*; D005344:Fibrinopeptide A / Q000378:metabolism; D005615:Freezing; D006801:Humans; D017713:Platelet Transfusion
D000925:Anticoagulants; D001798:Blood Proteins; D002951:Citrates; D003176:Complement C3; D005344:Fibrinopeptide A; D019343:Citric Acid; D015926:Complement C3a; D005169:Factor VIII